TOP > 外国特許検索 > REAGENT FOR CANCER TESTING, AND CANCER TESTING METHOD

REAGENT FOR CANCER TESTING, AND CANCER TESTING METHOD

外国特許コード F130007585
整理番号 S2013-0341-N0
掲載日 2013年7月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2012JP065993
国際公開番号 WO 2012176879
国際出願日 平成24年6月22日(2012.6.22)
国際公開日 平成24年12月27日(2012.12.27)
優先権データ
  • 201161500816 (2011.6.24) US
発明の名称 (英語) REAGENT FOR CANCER TESTING, AND CANCER TESTING METHOD
発明の概要(英語) Provided are: a peptide set comprised of tumor antigen-derived peptides that bind to HLA class I molecules; a bead or an ELISA plate to which are bound tumor antigen-derived peptides that bind to HLA class I molecules; a kit for measuring antibody titer against tumor antigen-derived peptides that bind to HLA class I molecules; a method of using tumor-antigen derived peptides that bond to HLA class I molecules in the diagnosis of cancer; and a method of using tumor-antigen derived peptides that bond to HLA class I molecules in predicting the prognosis of cancer patients.
従来技術、競合技術の概要(英語) BACKGROUND ART
1 Fourth leading cause of death of the malignant tumor can be at Japanese occupies about 33 million people die each year. About 600 million cases per year in the world died in cancer. In the treatment of cancer, surgical resection, such as anti-cancer agents and radiation therapy is performed. However such therapy involves the problem of recurrence and QOL, and further the method for the treatment of cancer progression that are not available with choices such as no problem. Immunotherapy for cancer (vaccine therapy) for a longer period as the first method for the treatment of deficiencies of 4 are. Cancer peptide vaccine in therapy is believed to be the major effector cell-mediated immunity has T cells specific for human leukocyte antigen (HLA) restricted and, only patients with a particular HLA type and including the inventors vaccine development has been in the world. Already HLA-A24, - A2, and supertype HLA-A3 - A26 (HLA-A3, - A11, - A31, and - A68.1 - A33) and coupled to either, each have the ability to induce CTL to restricted HLA derived peptide is a tumor antigen identified, such peptides can be useful as a cancer peptide vaccines have been reported (non-patent document 1-3). These tumor antigen-derived peptide HLA class I binding peptide.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KURUME UNIVERSITY
  • 発明者(英語)
  • ITOH, Kyogo
  • SASADA, Tetsuro
  • MATSUEDA, Satoko
  • KOMATSU, Nobukazu
  • NOGUCHI, Masanori
  • YAMADA, Akira
  • SHICHIJO, Shigeki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
上記の特許・技術に関心のある方は、下記問い合わせ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close